⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

April 17, 2021JAMA OncologyOpen Access

Association Between KRAS Variant Status and Outcomes With First-line Immune Checkpoint Inhibitor–Based Therapy in Patients With Advanced Non–Small-Cell Lung Cancer

Lova Sun Miles Hsu Roger B. Cohen Corey J. Langer Ronac Mamtani Charu Aggarwal

View Full Paper

Ask AI

Bookmark

Share

Abstract

This cohort study examines the association of KRAS status with outcomes following immune checkpoint inhibition monotherapy vs chemoimmunotherapy.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Sun et al. (2021) studied this question.

synapsesocial.com/papers/6a759a181a44875efa600317 https://doi.org/10.1001/jamaoncol.2021.0546

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 related papers. Consider them for comparative context:

1The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicityCohort Study · 2019 · 281 citations
2Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNAOriginal Research · 2017 · 650 citations
3Comparison of Population Characteristics in Real-World Clinical Oncology Databases in the US: Flatiron Health, SEER, and NPCROriginal Research · 2020 · 358 citations
4Rilvegostomig Plus Trastuzumab-Deruxtecan for Early-Stage Breast CancerJAMA Oncology · Thu,
5“Low-Risk” Ovarian Lesions—The Case for Early Follow-UpJAMA Oncology · Thu,

More from JAMA Oncology

Long-Term Outcomes of De-Escalated 30-Gy Elective Irradiation in HPV-Associated Oropharyngeal CancerThu,
Neoadjuvant Stereotactic Ablative Radiotherapy Before Inferior Vena Cava Thrombectomy for Renal Cell CarcinomaThu,
Nivolumab-Ipilimumab for Localized Microsatellite Instability–High Gastric/Gastroesophageal Junction AdenocarcinomaThu,
Beyond Tumor Size, Toward Meaningful Patient Outcomes—Resisting RECISTThu,
Disitamab Vedotin Plus Tislelizumab in Transurethrally Unresectable, ERBB2 -Positive, Non–Muscle-Invasive Bladder CancerThu,